<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570635</url>
  </required_header>
  <id_info>
    <org_study_id>XL820-201</org_study_id>
    <nct_id>NCT00570635</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib</brief_title>
  <official_title>A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exelixis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exelixis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical benefit of the KIT inhibitor XL820 in
      subjects with advanced gastrointestinal stromal tumors (GIST) who are resistant to or
      intolerant of Imatinib and/or Sunitinib.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit, defined as either confirmed complete response, confirmed partial response, or evidence of stable disease lasting ≥16 weeks, in subjects with advanced GIST resistant to/intolerant of imatinib and/or sunitinib</measure>
    <time_frame>Assessed at baseline, Week 4 and 8, and every 8 weeks thereafter</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of XL820</measure>
    <time_frame>Assessed at each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival, duration of response, and overall survival</measure>
    <time_frame>Assessed until progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Further characterize the pharmacokinetic and pharmacodynamic parameters of XL820 in subjects with advanced GIST</measure>
    <time_frame>Assessed during periodic visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Gastrointestinal Stromal Tumors</condition>
  <condition>Gastrointestinal Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL820</intervention_name>
    <description>XL820 capsules administered orally as a single agent at a dose of 800 mg daily</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XL820</intervention_name>
    <description>XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic or locally advanced or unresectable GIST who have intolerance
             of or disease progression following prior treatment with imatinib and/or sunitinib

          -  ECOG (Eastern Cooperative Oncology Group) performance status ≤2

          -  Must have measurable disease per RECIST (Response Evaluation Criteria in Solid Tumors)

          -  Recovery from toxicity from prior therapy to Common Terminology Criteria for Adverse
             Events (CTCAE) v3.0 Grade ≤1 or to subject's baseline status

          -  Adequate organ and marrow function

          -  Sexually active subjects (male and female) must agree to use accepted methods of
             contraception during the course of the study and for 3 months following
             discontinuation of study drugs.

          -  Female subjects of childbearing potential must have a negative pregnancy test at
             enrollment.

        Exclusion Criteria:

          -  Therapy with imatinib or sunitinib within 14 days before the first dose of study drug

          -  Chemotherapy, immunotherapy, targeted therapy, chemoembolization, or any
             investigational drug for the treatment of GIST after the last dose of imatinib or
             sunitinib

          -  Anticoagulation with warfarin or coumarin-related compounds

          -  Radiation to ≥25% of bone marrow within 28 days of study entry

          -  Treatment with other investigational agents within 28 days of the first dose of XL820

          -  Known central nervous systems metastases

          -  Uncontrolled or intercurrent illness

          -  Pregnancy or breast-feeding

          -  Active bacterial or viral infection requiring systemic treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <disposition_first_submitted>May 30, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>May 30, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 7, 2013</disposition_first_posted>
  <last_update_submitted>May 30, 2013</last_update_submitted>
  <last_update_submitted_qc>May 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GIST</keyword>
  <keyword>Gastrointestinal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

